PMID- 33033525
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 11
IP  - 21
DP  - 2020
TI  - Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous 
      non-small cell lung cancer after failure of at least one prior systemic regimen.
PG  - 6421-6428
LID - 10.7150/jca.47072 [doi]
AB  - Background: Most patients with non-small cell lung cancer (NSCLC) experience 
      disease progression after first-line treatment. The efficacy and safety of the 
      nab-paclitaxel (nab-PTX) and bevacizumab combination as the second or further 
      line of treatment in patients with advanced NSCLC have not been reported yet. 
      Objective: To evaluate the efficacy and safety of the nab-PTX and bevacizumab 
      combination in patients with advanced non-squamous (NSQ) NSCLC after failure of 
      at least one prior systemic regimen. Methods: Patients with advanced (stage IV) 
      NSQ NSCLC who received the nab-PTX and bevacizumab combination as the second or 
      further line treatment between February 2012 and December 2018 at the Cancer 
      Hospital of the Chinese Academy of Medical Sciences (Beijing, China) were 
      included in this retrospective study. The main outcomes included the objective 
      response rate (ORR), progression-free survival (PFS), overall survival (OS), and 
      safety. Results: Thirty-four patients received 1-27 cycles (median, four cycles) 
      of treatment; 67.6% (23/34) patients had undergone at least two lines of previous 
      treatment. The ORR and disease control rates were 26.5% (9/34) and 82.4% (28/34), 
      respectively. The median PFS and OS were 6.0 (95% CI=2.9-7.2) and 11.0 (95% 
      CI=7.8-18.7) months, respectively. The multivariable analyses indicated that the 
      combined use of other drugs and pleural metastasis were respectively associated 
      with better PFS (hazard ratio=0.354, 95% CI=0.134-0.935, P=0.036) and OS (hazard 
      ratio=0.540, 95% CI=0.118-0.980, P=0.046). The most frequent grade 3-4 adverse 
      events (AEs) were neutropenia 20.6% (7/34), leukopenia 8.8% (3/34), and anemia 
      5.9% (2/34). No grade 5 AE occurred. Conclusion: Combined nab-PTX and bevacizumab 
      might be an effective treatment regimen for patients with advanced NSQ NSCLC 
      after failure of at least one prior systemic regimen, but studies have to 
      validate those findings.
CI  - (c) The author(s).
FAU - Hao, Xuezhi
AU  - Hao X
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
FAU - Zhu, Yixiang
AU  - Zhu Y
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
AD  - Affiliated Hospital of Guizhou Medical University, Guizhou Province Tumor 
      Hospital, Guiyang, P.R. China.
FAU - Mu, Yuxin
AU  - Mu Y
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
FAU - Wang, Shouzheng
AU  - Wang S
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
FAU - Li, Junling
AU  - Li J
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
FAU - Xing, Puyuan
AU  - Xing P
AD  - National Cancer Center/National Clinical Research Center For Cancer/Cancer 
      Hospital, Chinese Academy of Medical Science and Peking Union Medical College, 
      Beijing, 100021, China.
LA  - eng
PT  - Journal Article
DEP - 20200913
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC7532494
OTO - NOTNLM
OT  - adverse events
OT  - bevacizumab
OT  - carcinoma, non-small cell lung
OT  - nab-paclitaxel
OT  - survival
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2020/10/10 06:00
MHDA- 2020/10/10 06:01
PMCR- 2020/01/01
CRDT- 2020/10/09 05:38
PHST- 2020/04/15 00:00 [received]
PHST- 2020/07/10 00:00 [accepted]
PHST- 2020/10/09 05:38 [entrez]
PHST- 2020/10/10 06:00 [pubmed]
PHST- 2020/10/10 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - jcav11p6421 [pii]
AID - 10.7150/jca.47072 [doi]
PST - epublish
SO  - J Cancer. 2020 Sep 13;11(21):6421-6428. doi: 10.7150/jca.47072. eCollection 2020.